MX2008006750A - Nanoemulsiones de botulinum. - Google Patents

Nanoemulsiones de botulinum.

Info

Publication number
MX2008006750A
MX2008006750A MX2008006750A MX2008006750A MX2008006750A MX 2008006750 A MX2008006750 A MX 2008006750A MX 2008006750 A MX2008006750 A MX 2008006750A MX 2008006750 A MX2008006750 A MX 2008006750A MX 2008006750 A MX2008006750 A MX 2008006750A
Authority
MX
Mexico
Prior art keywords
nanoemulsions
present
cosmetic
botulinum
privacy
Prior art date
Application number
MX2008006750A
Other languages
English (en)
Inventor
Jonathan Edelson
Robert Nicolosi
Original Assignee
Univ Massachusetts Lowell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39283314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2008006750(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Massachusetts Lowell filed Critical Univ Massachusetts Lowell
Publication of MX2008006750A publication Critical patent/MX2008006750A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/21—Emulsions characterized by droplet sizes below 1 micron
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La modalidad descrita aquí son las nanoemulsiones relacionadas que comprenden toxinas de botulinum o botulínicas. En una modalidad, las nanoemulsiones se preparan por microfluidización a alta presión y comprenden una distribución de tamaño de partícula exclusivamente entre 10 y 300 nm. Las nanoemulsiones contempladas por la presente invención son útiles para el tratamiento cosmético y médico de los estados de contractura musculares. Por ejemplo, la toxina de tobulinum puede relajar los músculos faciales tal que las arrugas de la piel se vuelvan más suaves y menos notables. Además, la presente invención contempla una formulación cosmética que se puede auto-administrar, por ejemplo, en la privacidad de la casa de uno y sin supervisión médica.
MX2008006750A 2005-12-01 2006-12-01 Nanoemulsiones de botulinum. MX2008006750A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74113905P 2005-12-01 2005-12-01
PCT/US2006/046236 WO2008045107A2 (en) 2005-12-01 2006-12-01 Botulinum nanoemulsions

Publications (1)

Publication Number Publication Date
MX2008006750A true MX2008006750A (es) 2008-09-03

Family

ID=39283314

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2008006750A MX2008006750A (es) 2005-12-01 2006-12-01 Nanoemulsiones de botulinum.
MX2012011594A MX352961B (es) 2005-12-01 2008-05-26 Nanoemulsiones de botulinum.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012011594A MX352961B (es) 2005-12-01 2008-05-26 Nanoemulsiones de botulinum.

Country Status (18)

Country Link
US (1) US8318181B2 (es)
EP (3) EP3144013B1 (es)
JP (6) JP2009518307A (es)
KR (5) KR102110379B1 (es)
CN (2) CN101374498A (es)
AU (1) AU2006349377B2 (es)
BR (1) BRPI0619134B8 (es)
CA (1) CA2631927C (es)
DK (3) DK3144013T3 (es)
ES (3) ES2710781T3 (es)
HK (2) HK1200016A1 (es)
HU (3) HUE054852T2 (es)
IL (3) IL191734A (es)
MX (2) MX2008006750A (es)
PL (3) PL3295955T3 (es)
PT (3) PT1959994T (es)
TR (1) TR201901443T4 (es)
WO (1) WO2008045107A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116822A1 (en) * 2012-02-02 2013-08-08 Lipella Pharmaceuticals, Inc. Methods and compositions for treating gastric disorders
US20100104631A1 (en) * 2001-08-13 2010-04-29 Lipella Pharmaceuticals Inc. Method of treatment for bladder dysfunction
US7824693B2 (en) 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
US20120114697A1 (en) 2002-08-19 2012-05-10 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
CN101384247B (zh) 2005-07-18 2013-05-22 麻萨诸塞州洛厄尔大学 制备与使用纳米乳剂的组合物和方法
US9486408B2 (en) * 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
WO2008039245A2 (en) 2006-04-27 2008-04-03 Anterios, Inc. Assessment of the effects of topical administration of chemodenervating pharmaceuticals
WO2008016664A2 (en) * 2006-08-02 2008-02-07 University Of Massachusetts Lowell Compositions and methods for treating cancer with dacarbazine nanoemulsions
CN107080703A (zh) 2006-12-01 2017-08-22 安特里奥公司 肽纳米粒子和其用途
AU2007329579A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
EP2162117B1 (en) 2007-05-31 2018-02-21 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
EP2170400B1 (en) * 2007-07-10 2012-07-25 Medy-Tox, INC. Pharmaceutical liquid composition of botulinum toxin with improved stability
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
EP2280690A2 (en) * 2008-04-18 2011-02-09 Nanobio Corporation Methods for treating herpes virus infections
EP2293787A1 (en) * 2008-04-25 2011-03-16 Nanobio Corporation Nanoemulsions for treating fungal, yeast and mold infections
CN105147608B (zh) * 2008-06-26 2019-12-10 安特里奥公司 真皮递送
WO2010078403A2 (en) * 2008-12-30 2010-07-08 Lipella Pharmaceuticals Inc. Methods and compositions for diagnosing urological disorders
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
US20120328549A1 (en) 2011-01-24 2012-12-27 Anterios, Inc. Oil compositions
SG193970A1 (en) 2011-01-24 2013-11-29 Anterios Inc Nanoparticle compositions
US20120328701A1 (en) * 2011-01-24 2012-12-27 Anterios, Inc. Nanoparticle compositions, formulations thereof, and uses therefor
US20130123647A1 (en) 2011-05-03 2013-05-16 The Research Foundation Of State University Of New York Methods Useful in Optimizing the Treatment of Neuropathies and Targeting Tissues with Cosmetic Botulinum Injections
KR101135486B1 (ko) 2011-05-25 2012-04-13 함종욱 보툴리눔 에이형 독소의 액상제품
AU2012276512B2 (en) * 2011-06-27 2016-04-21 Sang Duck Kim Pharmaceutical composition for treating scars on the skin, and method for treating scars on the skin using same
BR112014001066A2 (pt) * 2011-07-20 2017-02-21 Allergan Inc toxinas botulínicas para uso em um método para tratamento de depósitos adiposos
EP3103472A1 (en) 2012-03-22 2016-12-14 ReVance Therapeutics, Inc. Method of treatment of wrinkles using topical chemodenervating agents
WO2015155703A2 (en) 2014-04-09 2015-10-15 Nanoceutica Laboratories Pvt. Ltd Composition and method of producing nanoformulation of water insoluble bioactives in aqueous base
WO2016021985A1 (ko) * 2014-08-07 2016-02-11 김상덕 보툴리눔 독소와 공기의 혼합물을 포함하는 안면 윤곽 교정용 조성물 및 이를 이용한 안면 윤곽 교정 방법
SG11201701619TA (en) * 2014-09-02 2017-03-30 American Silver Llc Botulinum toxin and colloidal silver particles
CN105534783A (zh) * 2015-12-29 2016-05-04 杭州芭黎雅医疗美容诊所有限公司 一种自体胶原童颜组合物以及用于制备该组合物的方法
JP2019535829A (ja) * 2016-11-21 2019-12-12 エイリオン セラピューティクス， インコーポレイテッド 大型薬剤の経皮送達
EP3843777A4 (en) 2018-08-28 2022-05-04 Ira Sanders THERAPEUTICS FOR THE SKIN
BR112021004550A2 (pt) 2018-09-13 2021-06-08 Eirion Therapeutics, Inc. usos de inibidores de inibidor de ativador de plasminogênio 1 (pai-1)
US20220105068A1 (en) 2018-09-13 2022-04-07 Eirion Therapeutics, Inc. Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor
KR101968873B1 (ko) * 2018-09-21 2019-04-29 아이큐어 주식회사 세포 침투 효과가 우수한 보툴리늄 유래 펩타이드를 포함하는 화장료 조성물
EP3969038A1 (en) 2019-05-14 2022-03-23 Eirion Therapeutics, Inc. Delaying peak effect and/or extending duration of response
US10851363B1 (en) * 2019-05-22 2020-12-01 Boke Zhang Multilayer nano-cell containing biomolecules
CN111110720B (zh) * 2020-01-18 2021-11-26 河南德盟医药科技有限公司 一种迷迭香精油纳米脂质体及其制备方法与应用
US20230405098A1 (en) * 2022-06-16 2023-12-21 Innomed Technologies, Inc. Type e botulinum toxin to treat botulism

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US296006A (en) 1884-04-01 John hoefleb
US4533254A (en) 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US4908154A (en) 1981-04-17 1990-03-13 Biotechnology Development Corporation Method of forming a microemulsion
US5651991A (en) 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
CH677886A5 (es) 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
US5401243A (en) 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US5652274A (en) 1991-03-01 1997-07-29 Martin; Alain Therapeutic-wound healing compositions and methods for preparing and using same
HU217625B (hu) 1991-05-03 2000-03-28 Raisio Benecol Ltd. Új eljárás szérum-koleszterinszint csökkentését szolgáló béta-szitosztanin-zsírsav-észterek és észterkeverékek, valamint ezeket tartalmazó élelmiszerek előállítására
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US7384918B2 (en) 1991-09-24 2008-06-10 Allergan, Inc. Botulinum toxin for treating muscle contracture
US6939852B2 (en) 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
EP0572080B1 (en) 1992-05-29 1995-11-15 Quest International B.V. Aqueous perfume oil microemulsions
EP0571677A1 (en) 1992-05-29 1993-12-01 Unilever Plc Aqueous parfume oil microemulsions
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US8187612B2 (en) 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
ES2078190B1 (es) 1994-05-20 1996-08-01 Cusi Lab Procedimiento para el recubrimiento de goticulas o particulas de tamaño nanometrico.
US5843334A (en) 1994-06-20 1998-12-01 Nippon Shinyaku Co., Ltd. Method of producing emulsions and an emulsification apparatus
US5672358A (en) 1994-06-21 1997-09-30 Ascent Pharmaceuticals, Inc. Controlled release aqueous emulsion
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US20020048596A1 (en) 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
FR2730932B1 (fr) 1995-02-27 1997-04-04 Oreal Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie
US6002961A (en) 1995-07-25 1999-12-14 Massachusetts Institute Of Technology Transdermal protein delivery using low-frequency sonophoresis
FR2755854B1 (fr) 1996-11-15 1998-12-24 Oreal Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations
FR2760970B1 (fr) 1997-03-18 2000-03-10 Oreal Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations
US5994414A (en) 1997-04-28 1999-11-30 Avon Products, Inc. Water-thin emulsion formed by high pressure homogenization process
GB9708066D0 (en) 1997-04-22 1997-06-11 Woolcombers Group Plc Compositions and their use
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
CN1321683C (zh) 1997-07-15 2007-06-20 科罗拉多大学董事会 神经毒素疗法在泌尿系及相关疾病治疗中的应用
US6007856A (en) 1997-08-08 1999-12-28 The Procter & Gamble Company Oil-in-water dispersions of β-carotene and other carotenoids stable against oxidation prepared from water-dispersible beadlets having high concentrations of carotenoid
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
EP1080720A4 (en) 1998-03-05 2002-06-05 Nippon Shinyaku Co Ltd FAT EMULSIONS FOR INHALATIVE ADMINISTRATION
US5965154A (en) 1998-03-17 1999-10-12 Plc Holding, L.L.C. Adhesive matrix type transdermal patch and method of manufacturing same
ATE372377T1 (de) 1998-03-30 2007-09-15 Mibelle Ag Cosmetics Verwendung von nanoemulsionen zur bestimmung der biokompatibilität von lipophilen stoffen im zellkultur-test und dafür geeignete nanoemulsionen
FI111513B (fi) 1998-05-06 2003-08-15 Raisio Benecol Oy Uudet fytosteroli- ja fytostanolirasvahappoesterikoostumukset, niitä sisältävät tuotteet sekä menetelmät niiden valmistamiseksi
US5932562A (en) 1998-05-26 1999-08-03 Washington University Sitostanol formulation to reduce cholesterol absorption and method for preparing and use of same
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6242001B1 (en) 1998-11-30 2001-06-05 Mcneil-Ppc, Inc. Method for producing dispersible sterol and stanol compounds
DE19856897A1 (de) 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
FR2787728B1 (fr) 1998-12-23 2001-01-26 Oreal Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2788007B1 (fr) 1999-01-05 2001-02-09 Oreal Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
US20040009936A1 (en) 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
AU5409699A (en) 1999-07-05 2001-01-22 Idea Ag A method for the improvement of transport across adaptable semi-permeable barriers
US6358917B1 (en) 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6429189B1 (en) 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
FR2804015B1 (fr) 2000-01-21 2005-12-23 Oreal Nanoemulsion contenant des lipides amphiphiles et un polymere non ionique et utilisations
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
FR2809010B1 (fr) 2000-05-22 2002-07-12 Oreal Nanoemulsion a base de polymeres anioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
US6670322B2 (en) 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20020155084A1 (en) 2000-06-02 2002-10-24 The Regents Of The University Of The Michigan Nanoemulsion formulations
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
FR2811561B1 (fr) 2000-07-13 2003-03-21 Oreal Composition, notamment cosmetique, renfermant la dhea et/ou un precurseur ou derive chimique ou biologique de celle-ci, et un inhibiteur de metalloproteinase
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
ES2291379T3 (es) 2000-12-27 2008-03-01 Ares Trading S.A. Nanoparticulas lipidicas anfifilicas para la incorporacion de peptidos y/o proteinas.
FI20010115A0 (fi) * 2001-01-18 2001-01-18 Orion Corp Menetelmä nanopartikkelien valmistamiseksi
FR2819427B1 (fr) 2001-01-18 2003-04-11 Oreal Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
US20040048836A1 (en) 2001-03-23 2004-03-11 Wilmott James M Method for preparing high pressure/ high shear dispersions containing physiologically active ingredients
KR100463167B1 (ko) 2001-04-13 2004-12-23 주식회사 태평양 고분자 나노입자를 이용한 경피흡수제 및 이를 함유한외용제 조성물
WO2004030608A2 (en) 2001-06-05 2004-04-15 The Regents Of The University Of Michigan Nanoemulsion vaccines
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
CN1258381C (zh) 2001-07-27 2006-06-07 路易斯安那州州立大学及农业机械学院管理委员会 用在痤疮治疗或预防中的肉毒杆菌毒素
AU2002323151A1 (en) * 2001-08-13 2003-03-03 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US20040224012A1 (en) 2001-10-05 2004-11-11 Pichit Suvanprakorn Topical application and methods for administration of active agents using liposome macro-beads
US20030113349A1 (en) 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US6861066B2 (en) 2002-03-11 2005-03-01 Health Plus International Inc. Method for the delivery of a biologically active agent
US6688311B2 (en) 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US6623780B1 (en) 2002-03-26 2003-09-23 Cargill, Inc. Aqueous dispersible sterol product
US20040115159A1 (en) 2002-03-29 2004-06-17 Tadlock Charles C Novel nanoemulsions
US7459164B2 (en) 2002-05-28 2008-12-02 Botulinum Toxin Research Associates, Inc. Composition for therapeutic and cosmetic botulinum toxin
US7691394B2 (en) 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
WO2003101483A1 (en) * 2002-05-31 2003-12-11 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
WO2003103633A1 (en) 2002-06-10 2003-12-18 Elan Pharma International, Ltd. Nanoparticulate sterol formulations and sterol combinations
US6996748B2 (en) 2002-06-29 2006-02-07 Intel Corporation Handling faults associated with operation of guest software in the virtual-machine architecture
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
JP4824311B2 (ja) 2002-09-12 2011-11-30 スリーエム イノベイティブ プロパティズ カンパニー 低温特性および耐溶剤性を有するフルオロエラストマー
US20040115727A1 (en) * 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
JP2006519761A (ja) 2002-12-20 2006-08-31 ボツリヌム・トクシン・リサーチ・アソシエイツ・インコーポレイテッド 改善された薬学的ボツリヌス毒素組成物
US7390505B2 (en) 2003-01-31 2008-06-24 Elan Pharma International, Ltd. Nanoparticulate topiramate formulations
EP1594552A2 (en) 2003-02-05 2005-11-16 Amphora Discovery Corporation Topical delivery of cosmetic agents
EP1599213A4 (en) 2003-02-24 2009-07-15 Ira Sanders CELL MEMBRANE TRANSLOCATION OF SNARE R GUL S INHIBITORS, ASSOCIATED COMPOSITIONS AND PATHOLOGY TREATMENT PROCESSES
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
WO2004084839A2 (en) 2003-03-24 2004-10-07 Cady Roger K Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
AU2004273779B2 (en) 2003-06-04 2009-10-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
WO2004112821A1 (ja) 2003-06-20 2004-12-29 Santen Pharmaceutical Co., Ltd. 筋緊張亢進性疾患の治療剤
WO2005013938A1 (ja) 2003-08-06 2005-02-17 Eisai Co., Ltd. 薬物超微粒子の製造法及び製造装置
CA2534426A1 (en) 2003-08-08 2005-02-17 Barnes-Jewish Hospital Emulsion particles for imaging and therapy and methods of use thereof
CH715855B1 (de) 2003-08-28 2020-08-14 Mibelle Ag Zubereitung bestehend aus mindestens zwei Nanoemulsionen.
EP1510206A1 (en) 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
AU2004285037B2 (en) 2003-10-29 2010-07-22 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
EP1547674A1 (en) 2003-12-23 2005-06-29 MediGene Oncology GmbH Method for producing colloidal nanoparticles
US6974579B2 (en) 2004-01-08 2005-12-13 Allergan, Inc. Methods for treating vascular disorders
AU2004316985A1 (en) 2004-02-23 2005-09-15 The Texas A & M University System Antioxidant compositions and methods of use thereof
ES2691498T3 (es) 2004-03-03 2018-11-27 Revance Therapeutics, Inc. Aplicación tópica y liberación transdérmica de toxinas botulínicas
US20050214325A1 (en) * 2004-03-26 2005-09-29 Vvii Newco 2003, Inc. Compositions and methods to increase the effect of a neurotoxin treatment
TW200603843A (en) 2004-04-20 2006-02-01 Technology Dev Company Ltd Tissue enhancement implant and method
US20050249686A1 (en) 2004-04-27 2005-11-10 Francoise Pataut Cosmetic composition free of water comprising fatty acid esters, petrolatum oil and non-ionic polymers
US7591806B2 (en) * 2004-05-18 2009-09-22 Bai Xu High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
US7228259B2 (en) 2004-06-30 2007-06-05 Lucent Technologies Inc. Method and apparatus for structure-preserving reduced-order modeling
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
AU2005274822B2 (en) 2004-07-26 2008-10-30 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
CA2518650A1 (en) 2004-09-10 2006-03-10 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US20060073208A1 (en) 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
CA2494473C (en) 2005-02-14 2007-06-26 Dpm Therapeutics Corp. Stabilized protein compositions for topical administration and methods of making same
PL1853303T3 (pl) 2005-02-14 2016-05-31 Dpm Therapeutics Corp Stabilizowane kompozycje do podawania miejscowego i sposoby ich otrzymywania
RU2007136616A (ru) 2005-03-03 2009-04-10 Риванс Терапьютикс, Инк. (Us) Композиция и способ для местного применения и чрескожного введения ботулинового токсина
EP1898947A2 (en) * 2005-06-14 2008-03-19 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
CN101384247B (zh) 2005-07-18 2013-05-22 麻萨诸塞州洛厄尔大学 制备与使用纳米乳剂的组合物和方法
WO2008051186A2 (en) 2005-08-09 2008-05-02 Nanobio Corporation Nanoemulsion containing compositions having ant i -inflammatory activity
US20090306198A1 (en) 2005-09-16 2009-12-10 Robert Nicolosi Anti-Oxidant Synergy Formulation Nanoemulsions to Treat Caner
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US20070148194A1 (en) 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
US20070178121A1 (en) 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
CA2645073A1 (en) 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
WO2008016664A2 (en) 2006-08-02 2008-02-07 University Of Massachusetts Lowell Compositions and methods for treating cancer with dacarbazine nanoemulsions
EP2271314A4 (en) 2008-03-28 2013-12-25 Univ Massachusetts COMPOSITIONS AND METHODS FOR PREPARING NANOEMULSIONS

Also Published As

Publication number Publication date
PL3144013T3 (pl) 2019-04-30
WO2008045107A3 (en) 2008-08-28
PT3144013T (pt) 2019-02-07
JP6523843B2 (ja) 2019-06-05
KR20170105635A (ko) 2017-09-19
EP3295955B1 (en) 2021-04-07
EP3144013A1 (en) 2017-03-22
HUE043423T2 (hu) 2019-08-28
KR101903920B1 (ko) 2018-11-13
PL1959994T3 (pl) 2018-02-28
JP2019108338A (ja) 2019-07-04
DK3144013T3 (en) 2019-03-04
IL269341A (en) 2019-11-28
JP2018024676A (ja) 2018-02-15
TR201901443T4 (tr) 2019-02-21
BRPI0619134B1 (pt) 2019-12-10
CA2631927C (en) 2015-08-18
HK1200016A1 (en) 2015-07-31
EP3295955A1 (en) 2018-03-21
CN101374498A (zh) 2009-02-25
AU2006349377B2 (en) 2013-06-27
PT3295955T (pt) 2021-07-12
CN103919690B (zh) 2020-07-31
HK1252485A1 (zh) 2019-05-24
AU2006349377A1 (en) 2008-04-17
US8318181B2 (en) 2012-11-27
JP6304940B2 (ja) 2018-04-04
DK1959994T3 (en) 2017-12-04
KR20200052989A (ko) 2020-05-15
IL248862B (en) 2019-10-31
IL248862A0 (en) 2017-01-31
HUE034677T2 (hu) 2018-02-28
JP2016006065A (ja) 2016-01-14
WO2008045107A2 (en) 2008-04-17
PT1959994T (pt) 2017-11-30
BRPI0619134A2 (pt) 2011-09-13
JP2020023500A (ja) 2020-02-13
US20120164182A1 (en) 2012-06-28
IL191734A (en) 2017-02-28
KR102110379B1 (ko) 2020-05-14
JP6841736B2 (ja) 2021-03-10
ES2648979T3 (es) 2018-01-09
EP1959994A2 (en) 2008-08-27
ES2710781T3 (es) 2019-04-26
CA2631927A1 (en) 2008-04-17
PL3295955T3 (pl) 2021-10-25
EP1959994B1 (en) 2017-08-30
KR101855550B1 (ko) 2018-05-04
EP3144013B1 (en) 2018-11-14
EP1959994A4 (en) 2012-08-01
IL269341B (en) 2021-03-25
IL191734A0 (en) 2008-12-29
DK3295955T3 (da) 2021-07-05
KR20130122016A (ko) 2013-11-06
MX352961B (es) 2017-12-15
BRPI0619134B8 (pt) 2021-05-25
ES2880281T3 (es) 2021-11-24
KR20080071615A (ko) 2008-08-04
HUE054852T2 (hu) 2021-10-28
JP2013189444A (ja) 2013-09-26
CN103919690A (zh) 2014-07-16
JP2009518307A (ja) 2009-05-07
KR20180108891A (ko) 2018-10-04

Similar Documents

Publication Publication Date Title
MX352961B (es) Nanoemulsiones de botulinum.
EA200801717A1 (ru) Композиция местного применения по уходу за кожей, продукт на ее основе и способ лечения
WO2010095118A3 (en) A cosmetic treatment method including the projection of an image onto the zone to be treated
HK1091151A1 (en) Cosmetic use of a composition containing at least one oxazoline, serving as an active substance, as a slimming product and/or for preventing and/or treating cellulite
WO2003020226A3 (en) Cosmetic compositions comprising nanoparticles and processes for using the same
WO2006048829A3 (en) Preparation of chitin and derivatives thereof for cosmetic and therapeutic use
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
MXPA02010941A (es) Composicion oxidante para el tratamiento de las fibras queratinicas que comprende una silicona aminada particular.
WO2003000193A3 (en) Covalent coupling of botulinum toxin with polyethylene glycol
ATE296124T1 (de) Haut/haar-äquivalent mit rekonstruierten papillen
WO2004017924A3 (en) Methods of treating involuntary facial spasms and facial wrinkles
WO2007078857A3 (en) Use of non-straight fibers dispersed in a composition and compositions thereof
MX2010004886A (es) Metodo para mejorar la apariencia de la piel usando particulas macroscopicas tratadas.
WO2007147731A3 (de) Handgerät zur kombinierten gesichtspflege
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
WO2009106338A3 (en) Cosmetic of dermopharmaceutical composition of mixed micelles
EP1951185A4 (en) TOPICAL FORMULATION WITH LATEX OR A FRACTION THEREOF AND COSMETIC TREATMENT PROCESS
WO2008145692A3 (en) Cosmetic composition comprising an active agent capable of stimulating tensin 1 expression
WO2009031099A3 (en) Cosmetic use of microorganisms
MXPA05010708A (es) Composicion farmaceutica que comprende un inmunosupresor para utilizarse en el tratamiento de enfermedades de la piel.
MX2009002224A (es) Composicion a base de xantoxilina y su utilizacion en cosmetica.
MXPA02010957A (es) Composicion reductora para el tratamiento de las fibras queratinicas que comprende una silicona aminada particular.
WO2007046038A3 (en) Cosmetic method for use in smoothing the skin
MX2007005615A (es) Agentes para el tratamiento del cabello o la piel que comprenden 3-piridinoles y/o 5-pirimidinoles.
TW200637604A (en) Cosmetic compositions containing sophora alopecuroides L. extracts

Legal Events

Date Code Title Description
FG Grant or registration